Maryland's Prescription Drug Affordability Board voted to cap how much government agencies pay for Jardiance, a common diabetes drug.
Maryland board votes to cap the cost of common diabetes drug Jardiance
The move is expected to save about $320,000 a year. A similar cap on Ozempic could save more money, with a goal of lowering costs for everyone in Maryland.
"Marylanders will see real relief at a time when people. At a time when people are stretched so thin and affordability challenges," says Senator Dawn Gile.
These limits apply to state and local government costs, but within the next year, the board could expand that power, potentially driving down prices for all Marylanders.
This story was reported on air by a journalist and has been converted to this platform with the assistance of AI. Our editorial team verifies all reporting on all platforms for fairness and accuracy.
